Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or a study of ruxolitinib in combination with panobinostat (LBH589) or siremadlin (HDM201) or rineterkib (LTT462) and are judged by the investigator to benefit from continued treatment

Next Previous
Trial Profile

An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or a study of ruxolitinib in combination with panobinostat (LBH589) or siremadlin (HDM201) or rineterkib (LTT462) and are judged by the investigator to benefit from continued treatment

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Panobinostat (Primary) ; Ruxolitinib (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

  • 19 Sep 2024 Status changed from recruiting to active, no longer recruiting.
  • 18 Apr 2024 This trial has been completed in Portugal , according to European Clinical Trials Database record.
  • 10 Jan 2024 This trial has been completed in Bulgaria, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top